Own the gold standard ✨ in financial data & analytics

Subscribe for $2
Overview
Profile
Nanovibronix - Stock

Nanovibronix Stock

NAOV
US63008J1088
A2QB7C

Price

0.72
Today +/-
+0
Today %
+0 %
P

Nanovibronix Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Nanovibronix, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Nanovibronix from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Nanovibronix’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Nanovibronix. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Nanovibronix’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Nanovibronix’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Nanovibronix’s growth potential.

Nanovibronix Revenue, EBIT and net profit per share

DateNanovibronix RevenueNanovibronix EBITNanovibronix Net Income
20232.28 M undefined-3.44 M undefined-3.71 M undefined
2022750,000 undefined-5.01 M undefined-5.45 M undefined
20211.7 M undefined-5.68 M undefined-14.28 M undefined
2020620,000 undefined-4.72 M undefined-4.33 M undefined
2019530,000 undefined-5.15 M undefined-5.79 M undefined
2018320,000 undefined-4.3 M undefined-4.15 M undefined
2017240,000 undefined-3.09 M undefined-5.81 M undefined
2016230,000 undefined-2.32 M undefined-2.83 M undefined
2015150,000 undefined-1.42 M undefined-2.88 M undefined
2014200,000 undefined-1.21 M undefined-2.65 M undefined
2013210,000 undefined-1.11 M undefined-1.99 M undefined
2012170,000 undefined-770,000 undefined-1.28 M undefined
201190,000 undefined-680,000 undefined-1.6 M undefined

Nanovibronix Stock Ratios

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (k)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2011201220132014201520162017201820192020202120222023
0000000000102
-------------
------------50.00
0000000000001,000
00-1-1-1-2-3-4-5-4-5-5-3
-----------500.00--150.00
-1-1-1-2-2-2-5-4-5-4-14-5-3
---100.00--150.00-20.0025.00-20.00250.00-64.29-40.00
0.180.180.180.010.10.230.250.190.210.511.261.421.75
- - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The Nanovibronix Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Nanovibronix is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Nanovibronix provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Nanovibronix's financial health and stability.

Assets

Nanovibronix's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Nanovibronix must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Nanovibronix after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Nanovibronix's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (k)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201120122013201420152016201720182019202020212022
0-1-1-2-2-2-4-4-5-4-14-5
000000000000
000000000000
00000000000-2
0011102020100
000000000000
000000000000
0000-1-1-2-3-3-3-4-7
000000000000
000000000000
000000000000
000000000000
1,00000000000000
000030604942
100030604942
------------
000000000000
00001-14-3060-5
-0.55-0.8-0.61-0.9-1.48-1.54-2.18-3.56-3.87-3.39-4.37-7.04
000000000000

Nanovibronix stock margins

The Nanovibronix margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Nanovibronix. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Nanovibronix.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Nanovibronix's sales revenue. A higher gross margin percentage indicates that the Nanovibronix retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Nanovibronix's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Nanovibronix's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Nanovibronix's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Nanovibronix. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Nanovibronix's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Nanovibronix Margin History

Nanovibronix Gross marginNanovibronix Profit marginNanovibronix EBIT marginNanovibronix Profit margin
202367.32 %-150.5 %-162.55 %
202222.67 %-668 %-726.67 %
202145.29 %-334.12 %-840 %
202033.87 %-761.29 %-698.39 %
201952.83 %-971.7 %-1,092.45 %
201850 %-1,343.75 %-1,296.88 %
201762.5 %-1,287.5 %-2,420.83 %
201660.87 %-1,008.7 %-1,230.43 %
201566.67 %-946.67 %-1,920 %
201455 %-605 %-1,325 %
201357.14 %-528.57 %-947.62 %
201270.59 %-452.94 %-752.94 %
201177.78 %-755.56 %-1,777.78 %

Nanovibronix Stock Sales Revenue, EBIT, Earnings per Share

The Nanovibronix earnings per share therefore indicates how much revenue Nanovibronix has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Nanovibronix earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Nanovibronix's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Nanovibronix’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Nanovibronix's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Nanovibronix Revenue, EBIT and net profit per share

DateNanovibronix Sales per ShareNanovibronix EBIT per shareNanovibronix Earnings per Share
20231.3 undefined-1.96 undefined-2.12 undefined
20220.53 undefined-3.53 undefined-3.84 undefined
20211.35 undefined-4.51 undefined-11.33 undefined
20201.22 undefined-9.25 undefined-8.49 undefined
20192.52 undefined-24.52 undefined-27.57 undefined
20181.68 undefined-22.63 undefined-21.84 undefined
20170.96 undefined-12.36 undefined-23.24 undefined
20161 undefined-10.09 undefined-12.3 undefined
20151.5 undefined-14.2 undefined-28.8 undefined
201420 undefined-121 undefined-265 undefined
20131.17 undefined-6.17 undefined-11.06 undefined
20120.94 undefined-4.28 undefined-7.11 undefined
20110.5 undefined-3.78 undefined-8.89 undefined

Nanovibronix business model

Nanovibronix Inc is a company that develops and manufactures medical technology. The company was founded in 2003 in New York and has since introduced a number of innovative products aimed at improving people's lives and their health. Nanovibronix Inc's business model focuses on the development of medical devices based on the patented technology platform of "low-intensity, low-frequency ultrasound." This unique technology utilizes vibrations in the low-frequency range to alleviate pain, heal wounds, reduce inflammation, and much more. The company has launched a wide range of products aimed at treating a variety of medical conditions. One of Nanovibronix Inc's key areas is pain relief. The company has introduced a range of products aimed at relieving pain, including devices for the treatment of acute and chronic pain, as well as specific devices for women to alleviate menstrual discomfort. Another focus of Nanovibronix Inc is wound care. The company has developed a range of products designed to contribute to wound healing, including an ultrasound patch for the treatment of chronic wounds and a device for faster and more effective healing of postoperative wounds. The company has also developed products for inflammation reduction. Inflammation can cause a variety of health problems, and Nanovibronix Inc aims to provide products that contribute to reducing inflammation. This includes devices for the treatment of arthritis and other inflammatory conditions. Nanovibronix Inc has a long history of innovation and progress. The company aims to change the way medical problems are treated by leveraging modern technology and research. Through continuous research and development of new products, Nanovibronix Inc has become a strong partner in the medical technology industry. Nanovibronix is one of the most popular companies on Eulerpool.com.

Nanovibronix SWOT Analysis

Strengths

Nanovibronix Inc possesses several strengths that contribute to its success in the market. These strengths include:

  • Advanced technology and innovative products
  • Strong intellectual property portfolio
  • Experienced and dedicated research and development team
  • Established brand reputation and customer trust
  • Effective marketing and distribution channels
  • Efficient supply chain management

Weaknesses

Despite its strengths, Nanovibronix Inc also faces certain weaknesses that need to be addressed. These weaknesses include:

  • Limited financial resources for expansion and growth
  • Heavy dependency on key suppliers
  • Relatively smaller market share compared to competitors
  • Product portfolio lacks diversification
  • Challenges in scaling manufacturing operations

Opportunities

Nanovibronix Inc can capitalize on various opportunities available in the market to further its growth. These opportunities include:

  • Increasing demand for non-invasive medical devices
  • Growing emphasis on home healthcare solutions
  • Rising healthcare expenditure worldwide
  • Expanding partnerships and collaborations with healthcare providers
  • Exploring untapped international markets

Threats

Nanovibronix Inc must also be aware of potential threats that could hinder its progress. These threats include:

  • Intense competition from larger and more established companies
  • Regulatory challenges and compliance requirements
  • Economic downturns affecting healthcare spending
  • Rapidly evolving market trends and customer preferences
  • Technological advancements by competitors
  • Barriers to market entry in certain geographical regions

Nanovibronix valuation based on historical P/E ratio, EBIT, and P/S ratio.

Nanovibronix shares outstanding

The number of shares was Nanovibronix in 2023 — This indicates how many shares 1.75 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Nanovibronix earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Nanovibronix's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Nanovibronix’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Nanovibronix's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Nanovibronix Stock splits

In Nanovibronix's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Nanovibronix.

Nanovibronix Earnings Surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20230 -0.42  (0 %)2023 Q3
9/30/2019-4.08 -2.4  (41.18 %)2019 Q3
6/30/2019-4.08 -3.2  (21.57 %)2019 Q2
12/31/2018-3.26 -3.6  (-10.29 %)2018 Q4
12/31/2016-0.11 -0.25  (-122.82 %)2016 Q4
9/30/2016-0.19 -0.13  (32.92 %)2016 Q3
1

Nanovibronix Stock Shareholders

%
Name
Stocks
Change
Date
1.48 % Renaissance Technologies LLC41,20041,20012/31/2023
1.09 % The Vanguard Group, Inc.30,1941,77812/31/2023
0.52 % Geode Capital Management, L.L.C.14,461012/31/2023
0.45 % AmTrust Financial Services, Inc.12,408012/31/2023
0.19 % Tower Research Capital LLC5,2622,13712/31/2023
0.14 % Jacob (Harold)3,827011/29/2023
0.13 % Fashek (Christopher M)3,750011/29/2023
0.13 % UBS Financial Services, Inc.3,537-5,33112/31/2023
0.05 % Schroeder (Maria)1,4581,45811/29/2023
0.01 % Brown (Stephen Russell)200011/29/2023
1
2
3
4

Nanovibronix Executives and Management Board

Mr. Brian Murphy66
Nanovibronix Chief Executive Officer, Director (since 2016)
Compensation 408,804
Mr. Stephen Brown66
Nanovibronix Chief Financial Officer
Compensation 298,601
Mr. Christopher Fashek73
Nanovibronix Independent Chairman of the Board
Compensation 189,782
Mr. Thomas Mika71
Nanovibronix Independent Director
Compensation 41,271
Hon. Michael Ferguson52
Nanovibronix Independent Director
Compensation 39,551
1
2

Nanovibronix Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Xiamen Comfort Science & Technology Group A - Stock
Xiamen Comfort Science & Technology Group A
SupplierCustomer-0,130,010,420,540,400,12
SANUWAVE Health - Stock
SANUWAVE Health
SupplierCustomer-0,460,090,600,220,20-
1

Nanovibronix stock: Frequently Asked Questions

What values and corporate philosophy does Nanovibronix represent?

Nanovibronix Inc represents core values of innovation, excellence, and customer satisfaction. With a strong corporate philosophy focused on improving patients' lives through cutting-edge medical devices and solutions, Nanovibronix Inc sets itself apart in the healthcare industry. The company thrives on continuous research and development, delivering advanced technologies that address unmet clinical needs. Nanovibronix Inc's commitment to improving patient outcomes and its dedication to providing healthcare professionals with effective tools make it a trusted partner. With a passion for creating impactful solutions, Nanovibronix Inc consistently demonstrates its commitment to enhancing the quality of life for patients globally.

In which countries and regions is Nanovibronix primarily present?

Nanovibronix Inc is primarily present in the United States and Israel.

What significant milestones has the company Nanovibronix achieved?

Nanovibronix Inc has achieved significant milestones in its journey. The company has successfully developed and commercialized innovative medical devices, focused on pain management and wound healing. It has received FDA clearance and approvals for several of its groundbreaking products, including PainShield® and WoundShield™. Nanovibronix Inc has also established strategic partnerships and collaborations, further enhancing its market presence and global reach. The company's commitment to research and development has led to advancements in therapeutic ultrasound technology, improving patient outcomes and quality of life. Nanovibronix Inc continues to revolutionize the medical industry with its cutting-edge solutions and remains poised for future growth and success.

What is the history and background of the company Nanovibronix?

Nanovibronix Inc, a reputable company in the stock market, boasts a rich history and background. With a drive for innovation and technological advancements, Nanovibronix Inc specializes in the development of medical devices using low-intensity surface acoustic wave technology. Founded in [insert year], the company has continuously aimed to revolutionize the healthcare industry by providing non-invasive and cost-effective solutions for various medical conditions. Nanovibronix Inc has garnered recognition for its cutting-edge products, including PainShield® and WoundShield™, which have shown exceptional efficacy in pain management and wound healing. With a steadfast commitment to improving patient outcomes, Nanovibronix Inc remains at the forefront of medical device innovation.

Who are the main competitors of Nanovibronix in the market?

The main competitors of Nanovibronix Inc in the market include companies such as Johnson & Johnson, Medtronic, Philips, and Siemens Healthineers.

In which industries is Nanovibronix primarily active?

Nanovibronix Inc primarily operates in the medical and healthcare industry.

What is the business model of Nanovibronix?

Nanovibronix Inc operates under a business model that centers around the development and commercialization of innovative medical devices. The company specializes in utilizing proprietary low-intensity ultrasound technology for various therapeutic applications. Nanovibronix Inc's products aim to provide non-invasive and drug-free solutions for pain relief, wound healing, and infection control. By leveraging ultrasound technology, the company aims to offer cost-effective and convenient alternatives to traditional treatment methods. Nanovibronix Inc is committed to advancing healthcare through its cutting-edge devices, contributing to improved patient outcomes and overall well-being.

What is the P/E ratio of Nanovibronix 2024?

The P/E ratio cannot be calculated for Nanovibronix at the moment.

What is the P/S ratio of Nanovibronix 2024?

The P/S cannot be calculated for Nanovibronix currently.

What is the AlleAktien quality score of Nanovibronix?

The AlleAktien quality score for Nanovibronix is 6/10.

What is the revenue of Nanovibronix 2024?

The revenue cannot currently be calculated for Nanovibronix.

How high is the profit of Nanovibronix 2024?

The profit cannot currently be calculated for Nanovibronix.

What is the business model of Nanovibronix

Nanovibronix Inc is a US-based company specializing in the development and manufacturing of medical devices and retail products. The company aims to develop and distribute innovative solutions for medical problems to help patients.

What is the Nanovibronix dividend?

Nanovibronix pays a dividend of 0 USD distributed over payouts per year.

How often does Nanovibronix pay dividends?

The dividend cannot currently be calculated for Nanovibronix or the company does not pay out a dividend.

What is the Nanovibronix ISIN?

The ISIN of Nanovibronix is US63008J1088.

What is the Nanovibronix WKN?

The WKN of Nanovibronix is A2QB7C.

What is the Nanovibronix ticker?

The ticker of Nanovibronix is NAOV.

How much dividend does Nanovibronix pay?

Over the past 12 months, Nanovibronix paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Nanovibronix is expected to pay a dividend of 0 USD.

What is the dividend yield of Nanovibronix?

The current dividend yield of Nanovibronix is .

When does Nanovibronix pay dividends?

Nanovibronix pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Nanovibronix?

Nanovibronix paid dividends every year for the past 0 years.

What is the dividend of Nanovibronix?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Nanovibronix located?

Nanovibronix is assigned to the 'Health' sector.

Wann musste ich die Aktien von Nanovibronix kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Nanovibronix from 7/10/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/10/2024.

When did Nanovibronix pay the last dividend?

The last dividend was paid out on 7/10/2024.

What was the dividend of Nanovibronix in the year 2023?

In the year 2023, Nanovibronix distributed 0 USD as dividends.

In which currency does Nanovibronix pay out the dividend?

The dividends of Nanovibronix are distributed in USD.

Other fundamentals and analyses of Nanovibronix in the deep dive.

Our stock analysis for Nanovibronix Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nanovibronix Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.